Suzuki T
Department of Pathology II, Fukushima Medical College, Japan.
Fukushima J Med Sci. 1992 Jun;38(1):19-33.
Malotilate, diisopropyl 1,3-dithiol-2-ylidenemalonate, is a relatively recently synthesized hepatotrophic chemical substance. Its inhibitory effect on rat liver cirrhosis induced by carbon tetrachloride (CCl4) was biochemically and morphologically investigated for 10 weeks, since this chemical had been reported to suppress liver damage caused by CCl4 or in vitro collagenogenesis of human fibroblasts. Concomitant administration of malotilate with CCl4 completely suppressed liver cell necrosis and markedly inhibited fatty change of hepatocytes in the first three weeks of the experiment. During the six to ten weeks of the experimental period, liver cirrhosis was perfectly inhibited by malotilate. Previously established liver cirrhosis, however, could not be normalized by malotilate treatment. Precise mechanism of the inhibitory effect of malotilate on liver cirrhosis is not elucidated, but this substance is clearly effective for preventing liver cell damage and/or liver cirrhosis caused by CCl4.
马洛替酯,即二异丙基1,3 - 二硫杂环戊烯 - 2 - 亚基丙二酸酯,是一种相对较新合成的肝营养化学物质。由于有报道称这种化学物质可抑制四氯化碳(CCl4)引起的肝损伤或人成纤维细胞的体外胶原生成,因此对其抑制CCl4诱导的大鼠肝硬化的作用进行了为期10周的生化和形态学研究。在实验的前三周,马洛替酯与CCl4联合给药完全抑制了肝细胞坏死,并显著抑制了肝细胞的脂肪变性。在实验的6至10周期间,马洛替酯完全抑制了肝硬化。然而,先前已形成的肝硬化不能通过马洛替酯治疗恢复正常。马洛替酯对肝硬化抑制作用的确切机制尚未阐明,但该物质对预防CCl4引起的肝细胞损伤和/或肝硬化显然有效。